Arctic Bioscience (No_rec, TP: NOK) - HeROPA-trial 1-year read-out
Arctic Bioscience announced 52-week results for the HeROPA trial (mild to moderate psoriasis). The results did not include detailed data and only a very limited number of the predefined secondary endpoints were described. It plans to present the full set of data from the study when the Clinical Study Report is ready in June. Based on the lack of detailed data, it is hard to draw conclusions, but based on what was presented, we view this as another setback for the company.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.